| Abstract |
[Abstract] Objective To compare the clinical comparison of escitalopram and mirtazapine in the treatment of depression. Methods A total of 140 patients with depression from March 2018 to March 2020 were selected as the study subjects. They were randomly divided into the control group and the study group according to random number table method. The study group was treated with escitalopram and the control group was treated with mirtazapine. The two groups of Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), Pittsburgh Sleep Quality Index (PSQI), Health Survey Short Form (SF-36), clinical efficacy, adverse reactions were compared. Results After 8 weeks of treatment, the HAMD, HAMA, and PSQI scores of the control group were significantly higher than that of the study group, and the SF-36 score was significantly lower than that of the study group, and the differences were statistically significant (P<0.05). The total effective rate of the control group was 84.29%, which was significantly lower than that of the study group, 95.71%, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the control group was 18.57%, which was significantly higher than that in the study group, 7.14%, the difference was statistically significant (P<0.05). Conclusion The clinical efficacy of escitalopram in the treatment of depression is significantly higher than that of mirtazapine, and it can also effectively improve patients sleep and quality of life, with fewer adverse reactions.
|